Highlights
Efficacy Excellence
In the efficacy population of the CART19-BE-02 trial, 84.4% of patients (27 of 32) achieved a complete response with undetected measurable residual disease (MRD) by day 28, utilizing a sensitivity threshold of 10^-5.
Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
